Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;15(7):862.
doi: 10.3390/genes15070862.

Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice

Florine M Wiss  1   2 , Deborah Jakober  1 , Markus L Lampert  1   2 , Samuel S Allemann  1
Affiliations

Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice

Florine M Wiss et al. Genes (Basel). .

Abstract

There is growing evidence that pharmacogenetic analysis can improve drug therapy for individual patients. In Switzerland, pharmacists are legally authorized to initiate pharmacogenetic tests. However, pharmacogenetic tests are rarely conducted in Swiss pharmacies. Therefore, we aimed to identify implementation strategies that facilitate the integration of a pharmacist-led pharmacogenetic service into clinical practice. To achieve this, we conducted semi-structured interviews with pharmacists and physicians regarding the implementation process of a pharmacist-led pharmacogenetic service. We utilized the Consolidated Framework for Implementation Research (CFIR) to identify potential facilitators and barriers in the implementation process. Additionally, we employed Expert Recommendations for Implementing Change (ERIC) to identify strategies mentioned in the interviews and used the CFIR-ERIC matching tool to identify additional strategies. We obtained interview responses from nine pharmacists and nine physicians. From these responses, we identified 7 CFIR constructs as facilitators and 12 as barriers. Some of the most commonly mentioned barriers included unclear procedures, lack of cost coverage by health care insurance, insufficient pharmacogenetics knowledge, lack of interprofessional collaboration, communication with the patient, and inadequate e-health technologies. Additionally, we identified 23 implementation strategies mentioned by interviewees using ERIC and 45 potential strategies using the CFIR-ERIC matching tool. In summary, we found that significant barriers hinder the implementation process of this new service. We hope that by highlighting potential implementation strategies, we can advance the integration of a pharmacist-led pharmacogenetic service in Switzerland.

Keywords: CFIR; ERIC; barrier; implementation; pharmacist; pharmacogenetics; strategy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest and no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Figures

Figure 1
Figure 1
Chapters of the semi-structured interview.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Haidar C.-E., Petry N., Oxencis C., Douglas J.S., Hoffman J.M. ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenomics. J. Am. Soc. Health-Syst. Pharm. 2022;79:704–707. doi: 10.1093/ajhp/zxab339. - DOI - PubMed
    1. Meyer zu Schwabedissen H.E. The Role of Pharmacogenomics in Individualized Medicine. In: Fischer T., Langanke M., Marschall P., Michl S., editors. Individualized Medicine: Ethical, Economical and Historical Perspectives. Springer International Publishing; Cham, Switzerland: 2015. pp. 93–112. Advances in Predictive, Preventive and Personalised Medicine.
    1. Whirl-Carrillo M., McDonagh E., Hebert J., Gong L., Sangkuhl K., Thorn C., Altman R., Klein T. Pharmacogenomics Knowledge for Personalized Medicine. Clin. Pharmacol. Ther. 2012;92:414–417. doi: 10.1038/clpt.2012.96. - DOI - PMC - PubMed
    1. Swen J.J., van der Wouden C.H., Manson L.E., Abdullah-Koolmees H., Blagec K., Blagus T., Böhringer S., Cambon-Thomsen A., Cecchin E., Cheung K.-C., et al. A 12-Gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions: An Open-Label, Multicentre, Controlled, Cluster-Randomised Crossover Implementation Study. Lancet. 2023;401:347–356. doi: 10.1016/S0140-6736(22)01841-4. - DOI - PubMed
    1. van der Wouden C.H., Cambon-Thomsen A., Cecchin E., Cheung K.C., Dávila-Fajardo C.L., Deneer V.H., Dolžan V., Ingelman-Sundberg M., Jönsson S., Karlsson M.O., et al. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin. Pharmacol. Ther. 2017;101:341–358. doi: 10.1002/cpt.602. - DOI - PubMed

LinkOut - more resources